Last reviewed · How we verify
Debio 4326
Debio 4326 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.
Debio 4326 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells. Used for Advanced solid tumors (phase 3 development).
At a glance
| Generic name | Debio 4326 |
|---|---|
| Sponsor | Debiopharm International SA |
| Drug class | Mitochondrial complex I inhibitor |
| Target | Mitochondrial complex I (NADH dehydrogenase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug targets mitochondrial NADH dehydrogenase (complex I), impairing ATP production and triggering metabolic stress in tumor cells. This mechanism is particularly relevant in cancers with high metabolic demands or specific mitochondrial dependencies. The selective targeting aims to exploit metabolic vulnerabilities in malignant cells while minimizing effects on normal tissues.
Approved indications
- Advanced solid tumors (phase 3 development)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |